CRRTF (Crescita Therapeutics) Total Liabilities : $4.89 Mil (As of Sep. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Crescita Therapeutics Total Liabilities?

Crescita Therapeutics's Total Liabilities for the quarter that ended in Sep. 2024 was $4.89 Mil.

Crescita Therapeutics's quarterly Total Liabilities declined from Mar. 2024 ($4.38 Mil) to Jun. 2024 ($4.20 Mil) but then increased from Jun. 2024 ($4.20 Mil) to Sep. 2024 ($4.89 Mil).

Crescita Therapeutics's annual Total Liabilities declined from Dec. 2021 ($6.56 Mil) to Dec. 2022 ($5.44 Mil) and declined from Dec. 2022 ($5.44 Mil) to Dec. 2023 ($4.31 Mil).

Crescita Therapeutics Total Liabilities Historical Data

The historical data trend for Crescita Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Crescita Therapeutics Total Liabilities Chart

Crescita Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

4.35

4.45

6.56

5.44

4.31

Crescita Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Liabilities	Get a 7-Day Free Trial															4.62	4.31	4.38	4.20	4.89

Crescita Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Crescita Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	3.626	+	(0.607	+	0.072
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	4.31

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	18.335	-	14.03
	=	4.31

Crescita Therapeutics's Total Liabilities for the quarter that ended in Sep. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	4.457	+	(0.349	+	0.083
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	4.89

Total Liabilities	=	Total Assets (Q: Sep. 2024 )	-	Total Equity (Q: Sep. 2024 )
	=	16.745	-	11.857
	=	4.89

Crescita Therapeutics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Crescita Therapeutics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Crescita Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Crescita Therapeutics Inc (OTCPK:CRRTF) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

CTX:Canada

Address

2805, Place Louis-R-Renaud, Laval, QC, CAN, H7V 0A3

Website

https://www.crescitatherapeutics.com

Crescita Therapeutics Inc is a Canadian commercial dermatology company with in-house research & development and manufacturing capabilities. The company offers a portfolio of non-prescription skincare products and early to commercial-stage prescription drug products and owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active ingredients into or through the skin. The company has three reportable segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The firm generates its revenue from Commercial Skincare Product Sales in Canada.